High Sensitivity C-Reactive Protein an inflammatory marker and lipoprotein levels in patients with coronary heart disease
Abstract
Background: C-Reactive Protein is a good marker of systemic inflammation which can be measured easily. Atherosclerosis lesions are intimal thickening of arteries. Inflammatory and immune cells constitute an important part of atheroma. C-RP levels at the upper end of the normal range indicate that a low level of inflammatory response has been initiated. Measurment of hs CRP provides a method to assess the risk of cardiovascular disease very early in life.
Aim: Estimation of High sensitivity C-Reactive Protein (HS-CRP) levels which is a marker of inflammation in serum of normal people and patients with past history of myocardial infarction.
Materials and Methods: Twenty six serum samples from patients with coronary heart disease (who had previous history of Myocardial Infarction) and twenty-one control samples and were included in the study. High sensitivity C-reactive protein and lipoprotein profile were estimated in patients with coronary heart disease and in age matched controls. Statistical Analysis- All data were represented as mean ± SD. Experimental data were statistically analyzed by students t’-test. For all analysis statistical significance was considered as p < 0.05.
Results: Mean hs C-RP level is significantly elevated in patients who had myocardial infarction when compared with age matched controls. Total cholesterol, LDL cholesterol also found to be increased in individuals who had myocardial infarction.
Conclusion: Inflammation plays an important role in myocardial infarction. Increased risk of MI is seen in those individuals who have higher levels of hsC-RP. There is also increase in total cholesterol and LDL cholesterol in subjects who had myocardial infarction when compared to controls. Coronary artery disease may be prevented by reducing the inflammation in addition to reducing the LDL cholesterol
Downloads
References
2. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10. [PubMed]
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. [PubMed]
4. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994 Aug 18;331(7):417-24. [PubMed]
5. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000 Oct 19;343(16):1139-47. [PubMed]
6. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996 Nov 15;94(10):2373-80. [PubMed]
7. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004 Apr 1;350(14):1387-97. [PubMed]
8. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003 Aug;49(8):1258-71. [PubMed]
9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65. [PubMed]
10. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004 Dec 16;351(25):2599-610. [PubMed]
11. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995 Sep 1;92(5):1355-74. [PubMed]
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43. [PubMed]
13. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003 Jan 28;107(3):363-9. [PubMed]
14. Stary HC, Chandler B, Glagov S, et al., A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the council on Atherosclerosis, American Heart Association. Circulation. 1994; 89: 2462 - 78.
15. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986 Mar-Apr;6(2):131-8.
16. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995 Sep 1;92(5):1084-8.
17. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996 Oct 15;94(8):2013-20. [PubMed]
18. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8264-8. [PubMed]
19. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol. 2002 Feb;14(1):123-8. [PubMed]
20. Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol. 2008 Feb;172(2):275-83. doi: 10.2353/ajpath.2008.070563. Epub 2008 Jan 10. [PubMed]
21. Procedure manual Vitros 5,1 FS.
22. Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19-26;420(6917):868-74. [PubMed]
23. Pearson TA, Mensah GA, Alexander RW, et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professional from the centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
24. Pearson TA, Mensah GA, Alexander RW, et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice:a statement for healthcare professionals from the centers for disease control and prevention and the American Heart association. Circulation 2003; 107: 499- 511.
25. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1071-80.
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001-9.
27. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58.
OAI - Open Archives Initiative
